Fubotv earnings beat by $0.10, revenue topped estimates
Vivek Ramaswamy, a ten percent owner of Roivant Sciences Ltd (NASDAQ:ROIV), sold a total of 1,142,273 common shares in two separate transactions, according to a Form 4 filing with the Securities and Exchange Commission. The sales amounted to approximately $13.08 million. According to InvestingPro data, the company maintains strong financial health with a current ratio of 33.47 and holds more cash than debt on its balance sheet.
On June 18, 2025, Ramaswamy sold 565,266 shares at a weighted average price of $11.45, in multiple transactions at prices ranging from $11.41 to $11.53. Following this transaction, Ramaswamy directly held 37,861,115 Roivant Sciences shares.
The second sale occurred on June 20, 2025, with Ramaswamy selling 577,007 shares at a weighted average price of $11.46, in multiple transactions at prices ranging from $11.45 to $11.54. This sale reduced Ramaswamy’s direct holdings to 37,284,108 shares.
The filing also indicates that Ramaswamy indirectly holds 13,357,857 shares through spousal ownership. Get comprehensive insider trading analysis and 10+ additional ProTips for ROIV with InvestingPro, including detailed insights on management’s share buyback activities.
In other recent news, Roivant Sciences has been the focus of several analyst reviews and clinical developments. Cantor Fitzgerald reiterated its overweight rating on Roivant Sciences, expressing confidence in the company’s oral TYK2/JAK1 inhibitor brepocitinib for dermatomyositis, with Phase 3 trial results expected in late 2025. H.C. Wainwright also maintained its buy rating and $18 price target, emphasizing the potential market expansion for brepocitinib in dermatomyositis and its unique mechanism compared to other JAK inhibitors. Guggenheim echoed a buy rating, noting brepocitinib’s promising prospects in dermatomyositis, potentially generating over $1 billion in sales if approved. Additionally, Roivant’s subsidiary, Pulmovant, reported positive Phase 1 data for mosliciguat, an inhaled treatment for pulmonary hypertension, showing good tolerance and no serious side effects. The company is advancing this treatment into Phase 2 trials. These developments, alongside Roivant’s strategic focus on new therapeutic areas and its ongoing patent litigation, were discussed in a dialogue with H.C. Wainwright, highlighting Roivant’s strong financial position for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.